Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Statement re September Factsheet

20 Oct 2015 07:00

RNS Number : 7360C
BlueCrest AllBlue Fund Ltd
20 October 2015
 



FOR IMMEDIATE RELEASE

 

20 October 2015

 

BLUECREST ALLBLUE FUND LIMITED

FACTSHEET - SEPTEMBER 2015

"A solid performance against difficult markets"

 

BlueCrest AllBlue Fund Limited (BCAB) rose by 0.3% in September, a solid performance against a backdrop of difficult markets, bringing the gain for the year to date to 2.9% (Sterling Class NAV). The rolling 12 month return remained level at 3.8% and volatility was stable, at 3.2%.

 

Markets were nervous and choppy as economic data remained generally disappointing, particularly from China. Emerging markets continued to feel the strain and the MSCI Emerging Markets index finished September down 17% on a year to date basis. Credit markets also suffered and exhibited some illiquidity, particularly in high yield. The US Federal Reserve keeping rates unchanged did nothing to settle investors' stomachs.

 

"Strongest performance came from BlueTrend 2x"

 

As in August, five of the seven underlying strategies generated positive performance. BlueCrest Multi Strategy Credit and BlueCrest Quantitative Equity detracted once again, albeit only modestly.

 

The strongest performance came from BlueTrend 2x, which rose by over 4.5% on the month. Although only three of BlueTrend's seven strategies produced positive performance, the four detracting strategies did little to dent to strong gains coming from long positioning in bonds, an orientation which was maintained by the model for the entire month. Strong performance was also seen from the short term interest rates sector. Positioning in equities and commodities was maintained net short. Overall risk levels increased slightly during the month.

 

Despite the turmoil in emerging markets, BlueCrest Emerging Markets Fund eked out a small gain. BlueCrest Multi Strategy Credit was the worst performing fund in September at -0.6% on the month. Gains were seen in volatility trading and convertible bond arbitrage with losses in long/short strategies. High yield positioning was largely flat despite illiquidity in the cash bond market seeing some sharp price falls. The risk exposure in the fund was already defensive entering September and there were further modest tactical risk reductions during the month.

 

BlueCrest Mercantile produced a small positive return as both the Trade Credit Opportunities and Bank Basel III strategies were positive. The former saw the Ukrainian sovereign CDS hedges triggered by default but the underlying trade finance positions pay out in full. The Bank Basel III strategy produced the majority of returns as emerging market mark-downs were offset by CDS hedge protection. Small losses were seen from some mining positions. A good pipeline of securitisations is being seen which are expected to become available by year end.

 

A small increase of 1.5% was made to the allocation to BlueCrest Equity Strategies for October at the expense of BlueTrend 2x and BlueCrest Capital International.

 

"The Company continued its buyback"

 

The Company continued its buyback activity during September, although selling pressure has subsequently abated. The discount remains reasonably stable, either side of 5%.

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

 

JTC (Guernsey) Limited

Secretary

 

Tel: Guernsey 01481 702400

 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRUKAVRVAARAAA
Date   Source Headline
1st Nov 20232:02 pmRNSCompany Update
27th Oct 20235:30 pmRNSHighbridge Tactical Credit Fund
18th Oct 20231:37 pmRNSCompany Update
3rd Oct 20239:36 amRNSDirector Declaration
28th Apr 20232:33 pmRNSTotal Voting Rights
17th Apr 20237:00 amRNSShares in issue
30th Mar 20235:02 pmRNSHalf-year Report
29th Mar 20232:11 pmRNSReturn of Capital
29th Mar 20232:08 pmRNSCash Distribution
17th Mar 20234:35 pmRNSPrice Monitoring Extension
17th Mar 20237:00 amRNSDirector Declaration
16th Mar 20237:00 amRNSCompany Update and Return of Capital Information
15th Mar 20234:36 pmRNS2019 Redemption Portfolio
15th Mar 20234:30 pmRNSNet Asset Value(s)
7th Mar 20234:35 pmRNSPrice Monitoring Extension
13th Feb 20239:00 amRNSChange of Registered Office
2nd Dec 202211:44 amRNSResult of AGM
21st Nov 20223:05 pmRNSHolding(s) in Company
9th Nov 20227:00 amRNSNotice of AGM
8th Nov 20224:00 pmRNSNet Asset Value(s)
8th Nov 20224:00 pmRNS2019 Redemption Portfolio
7th Nov 20225:00 pmRNS2019 Redemption Portfolio
7th Nov 20224:58 pmRNSNet Asset Value(s)
2nd Nov 20227:00 amRNSDistribution
31st Oct 20223:22 pmRNSAnnual Financial Report
20th Oct 202210:47 amRNSAudit Opinion
18th Oct 202211:04 amRNSNet Asset Value(s)
18th Oct 202211:03 amRNS2019 Redemption Portfolio
25th Aug 20224:50 pmRNSNet Asset Value(s)
25th Aug 20224:41 pmRNS2019 Redemption Portfolio
1st Aug 20229:51 amRNS2019 Redemption Portfolio
1st Aug 20229:45 amRNSNet Asset Value(s)
5th Jul 202211:09 amRNS2019 Redemption Portfolio
5th Jul 202211:03 amRNSNet Asset Value(s)
1st Jun 202211:22 amRNSNet Asset Value(s)
1st Jun 202211:20 amRNS2019 Redemption Portfolio
7th Apr 20228:38 amRNSNet Asset Value(s)
7th Apr 20228:24 amRNS2019 Redemption Portfolio
25th Mar 202211:22 amRNSNet Asset Value(s)
25th Mar 202211:15 amRNS2019 Redemption Portfolio
22nd Mar 202211:00 amRNSCash Exit Payment
21st Mar 20223:02 pmRNSInterim Report and Accounts
2nd Mar 202210:23 amRNS2019 Redemption Portfolio
2nd Mar 202210:20 amRNSNet Asset Value(s)
23rd Feb 20224:40 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
21st Feb 202211:21 amRNSHolding(s) in Company
20th Jan 20225:22 pmRNSHolding(s) in Company
6th Jan 20225:06 pmRNS2019 Redemption Portfolio
6th Jan 20224:59 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.